Comparative Pharmacology
Head-to-head clinical analysis: FOAMCOAT versus SSD AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOAMCOAT versus SSD AF.
FOAMCOAT vs SSD AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to bacterial DNA and cell wall components, causing disruption of cellular respiration and DNA replication. It also inhibits bacterial cell wall synthesis via the sulfadiazine component.
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
Apply a thin layer topically once or twice daily to affected area.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 6–8 hours; clinically, this supports twice-daily dosing in most patients.
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Renal: ~10% as unchanged drug; biliary/fecal: ~90% as metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic